NEUROSCIENTIST is a leading journal in the field of clinical neurology and neuroscience, published by SAGE Publications Inc. With an impressive impact factor reflected in its Q1 quartile ranking in both clinical neurology and miscellaneous neuroscience as of 2023, this journal positions itself as a crucial platform for the latest research and advancements in the neural sciences. Spanning from 1995 to 2024, NEUROSCIENTIST features a range of high-quality, peer-reviewed articles that cater to researchers, practitioners, and students alike. Although it does not offer Open Access options, the journal remains a vital resource owing to its Scopus rankings, situating it within the top percentile of its categories: ranked #28 out of 400 in clinical neurology and #15 out of 113 in general neuroscience. The journal's commitment to disseminating significant findings underlines its importance in fostering advancements in neurological understanding and treatment.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

SYNAPSE, an esteemed journal in the field of Cellular and Molecular Neuroscience, is published by Wiley and serves as a vital platform for disseminating groundbreaking research in neuroscience. Established in 1987, this journal has been pivotal in exploring the intricate mechanisms governing synaptic function and neural communication, contributing to our understanding of the nervous system. With an ISSN of 0887-4476 and an E-ISSN of 1098-2396, SYNAPSE is indexed in Scopus and currently holds a Q4 quartile ranking in its category, reflecting its niche yet significant presence within the research community. Despite its recent ranking in the 21st percentile among its peers, the journal’s commitment to quality and innovation remains unwavering. It is published from Hoboken, New Jersey, and although it is not an open-access journal, it provides invaluable insights and critical reviews that are pivotal for researchers, professionals, and students alike who seek to advance their knowledge in the dynamic field of neuroscience. Join us in contributing to the ever-evolving discourse in cellular and molecular neuroscience through SYNAPSE.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

BRAIN RESEARCH BULLETIN is a leading academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, dedicated to the dissemination of high-quality research in the interdisciplinary field of neuroscience. Since its inception in 1976, this journal has served as a vital platform for researchers, professionals, and students interested in a broad spectrum of topics within neuroscience, making significant contributions to the understanding of brain function and its associated disorders. With a commendable impact factor and a current Scopus rank of #35 out of 113 in general neuroscience, the journal holds a Q2 quartile ranking, underscoring its relevance and influence in the academic community. BRAIN RESEARCH BULLETIN invites submissions of original articles, reviews, and brief communications, enhancing scholarly communication within this dynamic field. Although the journal is not open access, it ensures widespread reach and impact through various subscription models, allowing access to pivotal findings that pave the way for future research advancements. For researchers aiming to share impactful discoveries and insights within the neuroscience community, BRAIN RESEARCH BULLETIN remains an essential outlet.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

Neural Regeneration Research is a premier Open Access journal, published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of Developmental Neuroscience. Since its inception, the journal has established itself as a valuable resource for researchers, professionals, and students alike, providing a comprehensive platform for disseminating the latest findings and methodologies in neural regeneration. With an impressive Scopus Ranks placement of #3 out of 49 in its category and a Q2 Quartile ranking, the journal boasts a significant impact within the academic community, reflecting its high quality and relevance. Since adopting an Open Access model in 2011, it has expanded access to critical research in neural regeneration, fostering collaboration and innovation among scholars globally. Covering various aspects of neuroscience, its converged years from 2006 to 2025 highlight the journal's commitment to ongoing discourse and discovery. Situated in China, the journal not only promotes local insights but also connects the global research community to pressing topics in neuroscience, making it an essential read for anyone involved in this dynamic field.

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

Acta Neuropathologica Communications is a distinguished open-access journal published by BMC since 2013, focusing on the rapidly advancing fields of neurology, cellular and molecular neuroscience, and pathology. Located in the United Kingdom, this journal serves as a vital platform for researchers to disseminate significant findings that enhance our understanding of neurological disorders and their underlying mechanisms. With an impressive impact factor reflected in its Q1 ranking across multiple relevant categories, including Cellular and Molecular Neuroscience, Neurology (Clinical), and Pathology and Forensic Medicine, Acta Neuropathologica Communications stands out in the academic community for its rigorous peer-review process and commitment to high-quality research. The journal’s Scopus rankings highlight its global relevance, placing it in the top percentiles among leading research publications. Researchers, professionals, and students alike are encouraged to access and contribute to this essential resource, fostering a collaborative and informed approach to tackling the complexities of neuropathology and neuroscience.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.